Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
LEVEL 1 STARTER
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 42.03 ▲ 0.08 (0.19%) | |
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Pfizer | PFE | NYSE | Ordinary Share |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.07% | 41.95 | 42.31 | 41.87 | 42.06 | 41.92 | 23:59:56 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 75,516 | 14,595,327 | $ 42.05 | $ 613,748,504 | 23,426,596 | 35.32 - 46.47 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:50:29 | 10 | $ 42.03 | USD |
Pfizer Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 233.24B | 5.56B | $ 11.15B | 1.90 | 22.10 | 5.55B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 1.44 | 3.43% | 05/09/2019 | -130.27k | 0.00% |
Pfizer News
Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures Business Wire • Fri May 24, 2019 4:00 PM (1 day ago)
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) • Fri May 17, 2019 3:50 PM (1 week ago)
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) • Fri May 17, 2019 3:50 PM (1 week ago)
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) • Fri May 17, 2019 3:50 PM (1 week ago)
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) • Fri May 17, 2019 3:50 PM (1 week ago)
FDA Approves Pfizer's Fragmin for Use as a Pediatric Anticoagulant Dow Jones News • Thu May 16, 2019 1:21 PM (1 week ago)
Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting Business Wire • Wed May 15, 2019 5:01 PM (1 week ago)
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PFE Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 41.27 | 42.305 | 41.25 | 41.6997 | 23M | 28M | 25M | 0.68 | 1.65% |
| 1 Month | 39.55 | 42.305 | 39.445 | 41.0739 | 17M | 33M | 24M | 2.4 | 6.07% |
| 3 Months | 43.47 | 43.79 | 38.42 | 41.4842 | 12M | 71M | 24M | -1.52 | -3.50% |
| 6 Months | 43.32 | 46.47 | 38.1 | 42.1155 | 12M | 71M | 24M | -1.37 | -3.16% |
| 1 Year | 35.96 | 46.47 | 35.32 | 41.5759 | 8M | 71M | 21M | 5.99 | 16.66% |
| 3 Years | 33.69 | 46.47 | 29.83 | 36.7777 | 6M | 113M | 20M | 8.26 | 24.52% |
| 5 Years | 29.93 | 46.47 | 27.51 | 34.4134 | 1k | 280M | 23M | 12.02 | 40.16% |
Pfizer Description
| Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments—Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare. |
